Stanley Druckenmiller Gilead Sciences, Inc. Transaction History

Duquesne Family Office LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $64 Million - $71.7 Million	-1,023,345 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $26.7 Million - $34.9 Million	-441,555 Reduced 30.14%	1,023,345 $64 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $18.5 Million - $20.5 Million	259,600 Added 21.54%	1,464,900 $113 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $78.2 Million - $91.2 Million	1,205,300 New	1,205,300 $85.4 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.